BioSpace News Archive

Jaya Biosciences, Inc. presented promising non-clinical data for a novel treatment approach in Alzheimer’s disease at the 23rd Annual Needham Virtual Healthcare Conference.

Aadi Bioscience, Inc. (NASDAQ: AADI) today announced it will present new non-clinical data that highlight the combinability of nab-sirolimus and its potential for synergy to enhance anti-cancer effects and overcome resistance.

Alcanza Clinical Research, a mission-focused investigator site network, has acquired Innovation Medical Research Center, a multi-specialty clinical research center.

Oakwood Chemical is thrilled to unveil its collaboration with EMP Biotech GmbH, a move set to streamline the oligo synthesis supply chain.

Valeos, a 501(c)(3) nonprofit organization designed to improve organ transplant outcomes for patients and organ donors through data collaboration, today announced the appointment of Dr. Stuart C. Sweet.

Gameto today provided an update on its clinical program for their lead asset, Fertilo, their novel investigational in vitro maturation (IVM) solution containing engineered ovarian support cells (OSC-IVM) to mature eggs outside of the body, and recent additions to its management team and scientific and clinical advisors.

Charles River Laboratories International, Inc. (NYSE: CRL) today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with Axovia Therapeutics Ltd . Charles River will manufacture High Quality (HQ) gene of interest plasmid to support the development of Axovia’s gene therapies for ciliopathies, including Bardet-Biedl Syndrome (BBS), a condition with limited treatment options and no cure.

bioAffinity Technologies, Inc. today announced the expansion of its partnership with the American Cancer Society (ACS) to raise funding for ACS’ Lung Quality Improvement (QI) initiative to increase the rate of lung cancer screening.

Medivir AB announces that the company will participate at the Investing in Oncology Forum on April 10, 2024.

Tome Biosciences, Inc. today announces the issuance of US Patent 11,952,571 for “Systems, Methods, and Compositions for Site-Specific Genetic Engineering Using Programmable Addition via Site-Specific Targeting Elements (PASTE)” by the US Patent and Trademark Office.